IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Rating of “Moderate Buy” by Analysts

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has received a consensus rating of “Moderate Buy” from the eighteen analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and fourteen have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $43.3571.

A number of equities analysts recently issued reports on the company. TD Cowen assumed coverage on IDEAYA Biosciences in a report on Tuesday, July 22nd. They issued a “buy” rating on the stock. JMP Securities assumed coverage on IDEAYA Biosciences in a report on Thursday, September 4th. They issued a “market outperform” rating and a $41.00 target price on the stock. JPMorgan Chase & Co. increased their target price on IDEAYA Biosciences from $72.00 to $74.00 and gave the stock an “overweight” rating in a report on Wednesday, September 3rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a report on Tuesday, September 9th. Finally, Mizuho increased their target price on IDEAYA Biosciences from $43.00 to $44.00 and gave the stock an “outperform” rating in a report on Friday, September 12th.

Hedge Funds Weigh In On IDEAYA Biosciences

Several large investors have recently bought and sold shares of IDYA. Millennium Management LLC lifted its stake in IDEAYA Biosciences by 345.2% during the 1st quarter. Millennium Management LLC now owns 547,637 shares of the company’s stock valued at $8,970,000 after acquiring an additional 424,625 shares in the last quarter. Ensign Peak Advisors Inc lifted its stake in IDEAYA Biosciences by 126.4% during the 2nd quarter. Ensign Peak Advisors Inc now owns 741,833 shares of the company’s stock valued at $15,593,000 after acquiring an additional 414,189 shares in the last quarter. Fiera Capital Corp lifted its stake in IDEAYA Biosciences by 26.6% during the 2nd quarter. Fiera Capital Corp now owns 1,532,269 shares of the company’s stock valued at $32,208,000 after acquiring an additional 322,404 shares in the last quarter. Algert Global LLC bought a new position in IDEAYA Biosciences during the 1st quarter valued at $5,024,000. Finally, Nuveen LLC bought a new position in IDEAYA Biosciences during the 1st quarter valued at $4,706,000. 98.29% of the stock is currently owned by institutional investors.

IDEAYA Biosciences Stock Up 5.7%

Shares of IDYA stock opened at $29.26 on Friday. IDEAYA Biosciences has a 52 week low of $13.45 and a 52 week high of $32.67. The firm has a 50 day moving average of $25.67 and a 200-day moving average of $22.20. The company has a market cap of $2.56 billion, a price-to-earnings ratio of -7.72 and a beta of 0.14.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.03). The company had revenue of $6.00 million during the quarter, compared to the consensus estimate of $3.48 million. During the same quarter in the prior year, the company posted ($0.68) EPS. The firm’s quarterly revenue was up NaN% compared to the same quarter last year. Analysts anticipate that IDEAYA Biosciences will post -3.07 earnings per share for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.